JULY 2022LIFE SCIENCES REVIEW 19I saw the market need and strived to share my regulatory knowledge with the companies in the US and Asia, based on my experience in the global regulatory landscape (US, EU, China, and Japan)have the resources to have an in-house regulatory team to support early drug development. Therefore, providing a tailored, start-to-end scope of regulatory consulting services can meet the needs and overcome the challenges companies face at early clinical development stages. To this end, BLA Regulatory can either work with the client together as a partner or provide them with all the services they may need as and when required. The main driving force that aids BLA Regulatory in guiding its clients from the IND/CTA to NDA/BLA regulations smoothly is its principal consulting partners from the biopharma industry and the FDA. With each partner having over 15 years of experience, the experts guide the customers about pharmaceutical regulations in many forms, whether as an evaluator/examiner from a regulator's perspective or as a highly experienced industry insider. The organization further provides clients with two consultants if they want: one, an ex-FDA reviewer, and the second, a drug development industry veteran. The combined expertise enables the clients to address the drug development issues and mitigate the potential risks in a way that soothes the needs of both the regulators and the drug companies. Additionally, some of the consultants are capable project managers who worked in multi-national, multi-language backgrounds. They bring cultural awareness and project execution expertise that encompasses basic research through IND and marketing approvals.As a nimble regulatory consulting service company, BLA Regulatory, in many ways, is an ideal fit, especially for smaller pharmaceutical start-ups and less experienced clinical-stage companies. The company pays undivided attention to its client's needs and provides reliable, fast, fully-attentive, and customized regulatory services. Their customers will never have to worry about any unforeseen complications and can potentially get IND/CTA clearance or NDA/BLA approvals for their drug smoothly and effectively.
< Page 9 | Page 11 >